Literature DB >> 15767561

Irritable bowel syndrome.

Robin C Spiller1.   

Abstract

Irritable bowel syndrome (IBS) is one of the most common 'functional' gastrointestinal disorders accounting for 3% of all primary care consultations, with a strong female predominance. Although most of the literature comes from Western industrialized societies, when it has been looked for, this disorder appears to be equally common in the Third World. It is characterized by chronic abdominal pain or discomfort associated with disordered bowel habit and visceral hypersensitivity. Anxiety and somatization are more common in IBS than in the general population and may encourage consultation; however, they correlate poorly with symptoms. Bacterial gastroenteritis may be followed by the development of IBS in 5-10% of patients, depending on the severity of initial illness and prior anxiety or depression. The Rome criteria allow reliable diagnosis provided that there are no 'alarm' features which mandate further investigation. Microscopic colitis and bile salt malabsorption can easily be mistaken for IBS, as can chronic infestations or infections which should be considered, while recognizing that these are extremely uncommon in westernized societies. Some patients respond to exclusion diets as lactose and wheat intolerance are common. Others with prominent anxiety and/or depression respond to psychotherapy or antidepressants. Diarrhoeal symptoms respond to loperamide and 5HT3 receptor antagonists, while constipation responds to 5HT4 agonists. Antispasmodics may have limited benefit in treating pain. Low-dose tricyclic antidepressants are also helpful in alleviating pain and anxiety, even in those without obvious psychiatric disorders. If diagnostic criteria are met, then once diagnosed, new diagnoses rarely appear.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767561     DOI: 10.1093/bmb/ldh039

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  20 in total

1.  Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial.

Authors:  Jinjoo Kim; Kumsun Cho; Joo Sung Kim; Hyun Chae Jung; Bumsik Kim; Myeong Soo Park; Geun Eog Ji; Joo-Youn Cho; Kyoung Sup Hong
Journal:  Food Sci Biotechnol       Date:  2019-12-23       Impact factor: 2.391

2.  Below the belt: approach to chronic pelvic pain.

Authors:  Risa Bordman; Bethany Jackson
Journal:  Can Fam Physician       Date:  2006-12       Impact factor: 3.275

Review 3.  Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.

Authors:  Tina Didari; Shilan Mozaffari; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

4.  Therapeutic action of 5-HT3 receptor antagonists targeting peritoneal macrophages in post-operative ileus.

Authors:  Toko Maehara; Kenjiro Matsumoto; Kazuhide Horiguchi; Makoto Kondo; Satoshi Iino; Shunji Horie; Takahisa Murata; Hirokazu Tsubone; Shoichi Shimada; Hiroshi Ozaki; Masatoshi Hori
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

5.  Marked elevations in pro-inflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome.

Authors:  Gerard Clarke; Peter Fitzgerald; Alan A Hennessy; Eugene M Cassidy; Eamonn M M Quigley; Paul Ross; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  J Lipid Res       Date:  2009-11-11       Impact factor: 5.922

6.  Chronic diarrhea in travelers.

Authors:  Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

Review 7.  Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review.

Authors:  Jun Shi; Yao Tong; Jian-Gang Shen; Hai-Xia Li
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  Abnormal endogenous pain modulation and somatic and visceral hypersensitivity in female patients with irritable bowel syndrome.

Authors:  Clive H Wilder-Smith; Joan Robert-Yap
Journal:  World J Gastroenterol       Date:  2007-07-21       Impact factor: 5.742

9.  Unbalanced expression of protease-activated receptors-1 and -2 in the colon of diarrhea-predominant irritable bowel syndrome patients.

Authors:  Zhao Xiang Bian; Zhi Li; Zhi Xin Huang; Man Zhang; Hong Li Chen; Hong Xi Xu; Joseph J Y Sung
Journal:  J Gastroenterol       Date:  2009-05-09       Impact factor: 7.527

10.  Interleukin-6 modulates colonic transepithelial ion transport in the stress-sensitive wistar kyoto rat.

Authors:  Dervla O'Malley; Timothy G Dinan; John F Cryan
Journal:  Front Pharmacol       Date:  2012-11-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.